A randomized clinical trial at Memorial Sloan Kettering Cancer Center (MSK) has shown that fecal microbiota transplants (FMTs)
8-Oct-2018 3:55 PM EDT Add to Favorites
Memorial Sloan Kettering Researchers Build a New Model of Genetically Engineered Immune Cells That May Combat Solid Tumors in the Future
Scientists at Memorial Sloan Kettering Cancer Center (MSK) announced that they have built a new model of genetically engineered immune cells in mice that may allow them to fight solid tumors.
14-Aug-2018 12:05 PM EDT Add to Favorites
Peter T. Meinke, PhD, an accomplished chemist with more than 30 years of industry and academic experience, has been selected to lead the Tri-Institutional Therapeutics Discovery Institute.
12-Jun-2018 12:05 PM EDT Add to Favorites
Microsatellite instability (MSI) and DNA mismatch repair (MMR) deficiencies can predict Lynch syndrome (LS) across tumor types, according to researchers from Memorial Sloan Kettering Cancer Center (MSK), who presented this retrospective data...
2-Jun-2018 8:00 AM EDT Add to Favorites
Firefighters Who Were Exposed to World Trade Center Debris Found to Have an Increased Risk for a Precancerous Condition
Researchers at Memorial Sloan Kettering (MSK) report that firefighters at the World Trade Center (WTC) scene in September 2001 were nearly twice as likely as the general population to have a multiple myeloma precursor condition called monoclonal...
2-May-2018 12:05 PM EDT Add to Favorites
Pivotal Results from Phase III Trial Show That the Combination of Ipilimumab and Nivolumab Increases Overall Survival in People with Kidney Cancer
Treating people with advanced metastatic kidney cancer using a combination of the immunotherapy drugs nivolumab (Opdivo®) and ipilimumab (Yervoy®) significantly increased overall survival versus treatment with sunitinib (Sutent®) alone, according...
21-Mar-2018 11:00 AM EDT Add to Favorites
Updated Data Confirms a Durable 75 Percent Overall Response Rate, by Blinded Independent Review, of Larotrectinib in Adults and Children with Tumors Harboring TRK Fusions
Larotrectinib, a highly selective TRK kinase inhibitor, shows rapid, potent, and durable efficacy in both adult and pediatric patients with solid tumors that harbor TRK fusions, regardless of tumor type or patient age, according to results from...
22-Feb-2018 10:05 AM EST Add to Favorites
Increased Breast Cancer Risk Seen in Postmenopausal Women with High Body-Fat Levels Despite Normal BMI
The risk of invasive breast cancer is increased in postmenopausal women with a normal body mass index (BMI) but higher levels of body fat, meaning that a large portion of the population has an unrecognized risk of developing cancer.
9-Feb-2018 12:05 PM EST Add to Favorites
see all news
2-Dec-2014 12:35 PM EST
9-Dec-2013 9:05 AM EST
3-Dec-2013 3:15 PM EST
20-Sep-2013 2:00 PM EDT
12-Mar-2013 6:00 PM EDT
28-Sep-2012 12:40 PM EDTsee all experts